Correction: Notice on Convening an Annual General Meeting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
100
Correction: Notice on Convening an Annual General Meeting of Shareholders of AB Amber Grid

The reason for correction: attachments correction.

As initiated and decided by the Board of Directors of AB Amber Grid (legal entity code 303090867, office address Savanorių pr. 28, LT-03116 Vilnius, Republic of Lithuania), the Annual General Meeting of Shareholders of AB Amber Grid will be convened at 10.00 a.m., 23 April 2019 , at the Company's head office (address: Savanorių pr. 28, Vilnius).

Draft Agenda of the Meeting:

  1. Annual Report of AB Amber Grid for 2018
  2. Auditor’s report on AB Amber Grid financial statements for 2018 and AB Amber Grid Annual Report 2018
  3. Approval of AB Amber Grid financial statements for 2018
  4. Approval of AB Amber Grid Profit (Loss) Allocation for 2018
  5. Amendment of remuneration of Independent board members of AB Amber Grid
  6. Approval of standard contract terms (standard contract forms) of AB Amber Grid Board members (without remuneration; with remuneration)

Shareholder registration will commence at 9.15 a.m., 23 April 2019. Shareholder registration will be closed at 9.45 a.m., 23 April 2019.

The Record Date of the General Meeting of Shareholders: 16 April 2019. To be entitled to attend and vote at the General Meeting of Shareholders, persons must be registered shareholders of the Company at the end of the Record Date of the General Meeting of Shareholders. Shareholders' Rights Record Date shall be 8 May 2019. Persons entitled to receive the dividend shall be the ones who will be shareholders of AB Amber Grid as of the end of the Shareholders' Rights Record Date.

To be entitled to participate and vote at the General Meeting of Shareholders, persons must provide their identification documents. Persons who are not shareholders of AB Amber Grid, shall in addition to the aforesaid documents present documents certifying their right to vote at the General Meeting of Shareholders.

A possibility of participating and voting in the General Meeting of Shareholders by electronic means of communication shall not be provided.

On 28 March 2019, the Board of Directors of the Company approved the draft agenda and draft decisions of the General Meeting of Shareholders (explanations if decision is not required):

1) Annual Report of AB Amber Grid for 2018

Submitted explanation: “Decision of the Annual General Meeting of Shareholders is not required. The Board submits Annual Report of the Company for 2018 to take account of (added).” (Annex 1) 

2) Auditor’s report on AB Amber Grid financial statements for 2018 and AB Amber Grid Annual Report 2018

Submitted explanation: “Decision of the Annual General Meeting of Shareholders is not required. When taking decisions regarding approval of AB Amber Grid financial statements for 2018, to take note of the opinion presented in the Independent auditor’s report to the shareholders of AB Amber Grid (added).” (Annex 1)

3) Approval of AB Amber Grid financial statements for 2018

Draft decision: “To approve AB Amber Grid financial statements for 2018 (added).” (Annex 1) 

4) Approval of AB Amber Grid Profit (Loss) Allocation for 2018

Draft decision: “To approve of AB Amber Grid Profit (Loss) Allocation for 2018 (added).“ (Annex 2) 

5) Amendment of remuneration of Independent Board members of AB Amber Grid

Draft decision: “From 1 April 2019 to set an hourly fee of 60 (sixty) euros (before tax) for an Independent board member of the company's board, up to a maximum amount of 1,200 (one thousand two hundred) euros per month (before tax). In case that an Independent board member would be elected the Chairman of the Board, set a maximum amount of 1,560 (one thousand five hundred sixty) euros per month (before tax).” 

6) Approval of standard contract terms (standard contract forms) of AB Amber Grid Board members (without remuneration; with remuneration)

Draft  decision: “To approve the terms and conditions of the standard contracts of the members of the Board (standard forms of contracts) (without remuneration; with remuneration) (attached)”

The shareholders may familiarise themselves with the Draft Resolutions of the General Meeting of Shareholders and supplementary material thereof, also with the implementation of the shareholders’ rights on working days from 2 p.m. until 4 p.m. (on Fridays until 3.15 p.m.) from 1 April 2019 at the office of AB Amber Grid at Savanorių pr. 28, LT-03116 Vilnius, tel. +370 5 2360855 These documents are also presented on the Central Database of Regulated  Information www.crib.lt and at Company’s website www.ambergrid.lt .

The shareholders of AB Amber Grid, whose shares are entitled to at least 1/20 of the total number of votes, shall have the right to supplement the agenda for the General Meeting of Shareholders. The proposal to supplement the agenda shall be submitted in writing and sent by registered mail or delivered to the head office of the Company to the address: Savanorių pr. 28, LT-03116 Vilnius (hereinafter “the Head Office”). Draft Resolutions on the proposed issues or, when it is not mandatory to adopt resolutions, explanatory notes on each proposed issue of the agenda of the General Meeting of Shareholders must be presented alongside with the proposal. The agenda will be supplemented if the proposal is received not later than on 8 April 2019.

The shareholders entitled to at least 1/20 of the total number of votes shall have the right, at any time before the General Meeting of Shareholders or during the Meeting, to propose in writing new draft resolutions on the items put on the agenda of the General Meeting of Shareholders. Such a proposals must be executed in writing and sent to the Company by registered mail or delivered to the Head Office of the Company. The proposal submitted during the course of the Meeting must be executed in writing and handed over to the Secretary of the General Meeting of Shareholders.

The shareholders shall have the right to submit questions to the Company in advance, but not later than till 17 April 2019, in relation to the issues on the agenda of the General Meeting of Shareholders to be held on 24 April 2019. Questions must be executed in writing and delivered to the Company by registered mail or to the Head Office of the Company. The Company will not present any answer to the question submitted by a shareholder personally to him in the case relevant information is available on the Company’s website.

Any shareholder shall be entitled to authorise a natural or legal person to participate and vote in his name at the General Meeting of Shareholders. The proxy of the shareholder must present the document confirming the person’s identity and the certified power of attorney as provided for by law, which must be delivered to the Head Office not later than before the end of the registration of the attendees of the General Meeting of Shareholders. During the General Meeting of Shareholders, the proxy exercises the same rights as the shareholder he is representing should. The form of the Power of Attorney to represent at the General Meeting of Shareholders is available on the website of the Company: www.ambergrid.lt .

On the issues on the agenda of the General Meeting of Shareholders, the Shareholders may vote in writing by filling in a General Ballot Paper. On the shareholder’s request, the Company, not later than 10 days before the day of the General Meeting of Shareholders, will send a General Ballot Paper by registered mail free of charge or submit it in person against signature to the shareholder. The shareholder or his proxy must undersign the filled in General Ballot Paper. If the General Ballot Paper is signed by a person who is not a shareholder, a document certifying his right to vote must be appended to the filled in Ballot Paper. The duly filled in General Ballot Paper must be delivered to the Company by registered mail or submitted against signature at the Head Office not later than before the end of registration of the attendees of the General Meeting of Shareholders. The form of the General Ballot Paper is available on the website of the Company: www.ambergrid.lt .

On the day of convocation of the General Meeting of the Shareholders the total number of shares was 178 382 514. All these shares grant voting right.

Information referred to in Article 26 2 of the Law on Companies of the Republic of Lithuania shall be available on the website of the Company: www.ambergrid.lt . Information about the additions to the agenda, as well as decisions made by the general meeting shall be also available on the Central Database of Regulated Information www.crib.lt

Annexes:

  1. AB Amber Grid audited financial statements for 2018, including Annual Report of AB Amber Grid for 2018, submitted together with the Corporate Governance Report form.
  2. Allocation of 2018 AB Amber Grid Profit (draft).
  3. Standard terms and conditions (forms) of the Board members of AB Amber Grid.
  4. AB Amber Grid Power of Attorney Form.
  5. AB Amber Grid Shareholder Ballot.
  6.  Confirmation of Responsible Persons.
  7. Report of Audit Committee of UAB “EPSO-G”.

The individual authorised by AB Amber Grid (the issuer) to provide additional information on the material event:

Giedrė Osinaitė Head of Legal Division tel. +370 5 2327733 fax +370 5 236 0850

e-mail: g.osinaite@ambergrid.lt

Attachments

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading